Target-directed cancer: protein-ligand interactions
Drug Target Review
NOVEMBER 1, 2023
We need to build the assays that we need for compound screening. Capivasertib originated from a collaboration between my former company Astex Pharmaceuticals and the ICR and was further developed by AstraZeneca. We are involved from a very early stage once a target is validated.
96 
Let's personalize your content